Oncology drug discovery: Planning a turnaround

Cancer Discovery

Volumn 4, Issue 4, 2014, Pages 397-404

  Toniatti, Carlo ^a   Jones, Philip ^a   Graham, Hilary ^a   Pagliara, Bruno ^b   Draetta, Giulio ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b On kòs Pharma Consulting   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 7 HYDROXYSTAUROSPORINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; CANCER VACCINE; CRIZOTINIB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; INIPARIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM; PROTEIN KINASE B; TAXANE DERIVATIVE; TIVANTINIB; VASCULOTROPIN;

ARTICLE; DISEASE MODEL; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS;

EID: 84897948088     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0452     Document Type: Article

References (57)

1. Pagliara B. An analysis of oncology drug success rates. Med Nous 2011; 5: 10-1.
2. Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol 2013; 31: 1904-11.
3. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-58.
4. MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol 2013; 31: 1815-24.
5. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013; 3: 1806-14.
6. Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013; 153: 17-37.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
9. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012; 72: 4875-82.
10. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013; 49: 1297-304.
11. Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 2013; 31: 1592-605.
12. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013; 12: 358-69.
13. Parkinson DR, Johnson BE, Sledge GW. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res 2012; 18: 619-24.
14. Majewski IJ, Bernards R. Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nat Med 2011; 17: 304-12.
15. Singh M, Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol 2012; 30: 648-57.
16. Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol 2005; 70: 419-26.
17. Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009; 30: 303-12.
18. Tammam J, Ware C, Efferson C, O'Neil J, Rao S, Qu X, et al. Downregulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol 2009; 158: 1183-95.
19. Dranoff G. Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol 2011; 12: 61-6.
20. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9: 338-50.
21. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483: 613-7.
22. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet 2013; 45: 747-55.
23. Blaug S, Chien C, Shuster MJ. Managing innovation: universityindustry partnerships and the licensing of the Harvard mouse. Nat Biotechnol 2004; 22: 761-4.
24. Politi K, Pao W. How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol 2011; 29: 2273-81.
25. Heyer J, Kwong LN, Lowe SW, Chin L. Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 2010; 10: 470-80.
26. Komlodi-Pasztor E, Sackett DL, Fojo AT. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a fl awed rationale. Clin Cancer Res 2012; 18: 51-63.
27. Kaelin WG Jr. Molecular biology. Use and abuse of RNAi to study mammalian gene function. Science 2012; 337: 421-2
28. Djaballah H. Editorial. Random RNAi screening data analysis: a call for standardization. Comb Chem High Throughput Screen 2012; 15: 685
29. Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 13: 821-34
30. Babij C, Zhang Y, Kurzeja RJ, Munzli A, Shehabeldin A, Fernando M, et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res 2011; 71: 5818-26.
31. Luo T, Masson K, Jaffe JD, Silkworth W, Ross NT, Scherer C A, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A 2012; 109: 2860-5.
32. Weïwer M, Spoonamore J, Wei J, Guichard B, Ross NT, Masson K, et al. A potent and selective quinoxalinone-based STK33 inhibitor does not show synthetic lethality in KRAS-dependent cells. ACS Med Chem Lett 2012; 3: 1034-8
33. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108-12.
34. Vangamudi B, Ayres AE, Burke JP, Waterson AG, Rossanese OW, Fesik SW. Evaluation of TBK1 as a novel cancer target in the K-Ras pathway. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; 2012. Abstract nr 1813.
35. Workman P, Collins I. Probing the probes: fitness factors for small molecule tools. Chem. Biol 2010; 17: 561-77.
36. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007; 13: 1955-60
37. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010; 70: 2146-57
38. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012; 18: 1655-62
39. Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bonafide PARP inhibitor. Clin Cancer Res 2012; 18: 510-23
40. Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013; 73: 3087-96
41. Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013; 19: 2381-92.
42. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nat Rev Drug Discov 2007; 6: 115-20
43. Fleck R, Bach D. Trends in personalized therapies in oncology: the (venture) capitalist's perspective. J Personalized Med 2012; 2: 15-34.
44. Medicines in Development: Cancer, PhRMA Research Report, 2012
45. Lackner MR, Wilson TR, Settleman J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol 2012; 8: 999-1014
46. Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev Drug Discov 2011; 10: 897-8.
47. Bornstein SR, Licinio J. Improving the efficacy of translational medicine by optimally integrating health care, academia and industry. Nat Med 2011; 17: 1567-9
48. Bubela T, FitzGerald GA, Gold ER. Recalibrating intellectual property rights to enhance translational research collaborations. Sci Transl Med 2012; 4: 122cm3.
49. Tralau-Stewart CJ, Wyatt CA, Kleyn DE, Ayad A. Drug discovery: new models for industry-academic partnerships. Drug Discov Today 2009; 14: 95-101.
50. Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today 2012; 17: 1088-102.
51. Barnes MR, Harland L, Foord SM, Hall MD, Dix I, Thomas S, et al. Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nat Rev Drug Discov 2009; 8: 701-8.
52. Wellenreuther R, Keppler D, Mumberg D, Ziegelbauer K, Lessl M. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare. Drug Discov Today 2012; 17: 1242-8.
53. T simberidou A M, Iskander N G, Hong D S, Wheler J J, F alchook G S, F u S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18: 6373-83.
54. Atkins MB, Hidalgo M, Stadler WM, Logan T F, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI- 779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-18
55. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2011; 9: 199-207.
56. Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 2012; 11: 201-14.
57. Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 2012; 9: 542-8